C9orf7/CACFD1 (E6E3J) Rabbit mAb #28284
- WB
- IP
Supporting Data
| REACTIVITY | H |
| SENSITIVITY | Endogenous |
| MW (kDa) | 19 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
- IP-Immunoprecipitation
Species Cross-Reactivity Key:
- H-Human
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:50 |
Storage
Protocol
Specificity / Sensitivity
C9orf7/CACFD1 (E6E3J) Rabbit mAb recognizes endogenous levels of total human C9orf7/CACFD1 protein. Based on the antigen sequence, this antibody is predicted to detect isoforms 1 and 2 of C9orf7/CACFD1 protein, but not isoforms 3 or 4.
Species Reactivity:
Human
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Leu168 of human C9orf7/CACFD1 protein.
Background
C9orf7/Calcium Channel Flower Domain Containing 1 (CACFD1), also known as Flower (FWE), is the human homolog of the Drosophila fwe gene. In Drosophila, expression of specific FWE membrane protein isoforms indicates the fitness of a cell during clonal selection and cell competition processes, which promotes the elimination of weaker cells from a growing population (1). In humans, there are four isoforms of C9orf7/CACFD1. Investigators have shown expression of human C9orf7/CACFD1 isoforms 1 and 3 indicates reduced cellular fitness compared to cells expressing isoforms 2 and 4, which provide a competitive advantage in survival. Moreover, human cancer cells show increased expression of isoforms 2 and 4 that confers a competitive growth advantage for cancer cells. Inhibition of C9orf7/CACFD1 expression reduces tumor growth and metastasis, and induces sensitivity to chemotherapy (2-5).
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.